Seaport Therapeutics · 1 day ago
Director, Statistical Programming
Seaport Therapeutics is a clinical-stage therapeutics company advancing the development of novel neuropsychiatric medicines. They are seeking a Director of Statistical Programming to build and lead the Statistical Programming function within the Biometrics department, focusing on vendor governance and ensuring high-quality, submission-ready deliverables.
BiotechnologyPharmaceuticalTherapeutics
Responsibilities
Lead the Statistical Programming function for Seaport Therapeutics; serve as programming representative on study and program teams and within the Biometrics leadership group
Provide strategic oversight and day-to-day governance of CROs and external programmers, including scope planning, timelines, quality metrics, and issue escalation
Perform hands-on programming in SAS or R to review/QC vendor deliverables, develop analysis datasets (SDTM/ADaM), and generate tables, listings, and figures (TLFs)
Ensure compliance with CDISC standards (SDTM, ADaM), FDA/EMA/ICH guidance, and submission requirements (e.g., define.xml, reviewer’s guides, eCTD packages)
Support regulatory interactions (IND, NDA/BLA/MAA), including ad hoc analyses, briefing package outputs, and responses to information requests
Partner with Biostatistics, Data Management, Clinical, and Safety to enable medical and safety monitoring, signal detection, and data-driven decision-making across ongoing trials
Establish and maintain programming processes, SOPs, work instructions, and reusable libraries/macros; champion automation, reproducibility, and audit readiness
Recruit, manage, mentor, and develop a team of statistical programmers as the portfolio grows; manage contractors/FSPs and oversee performance and career development
Drive continuous improvement across standards, tools, and infrastructure (SAS/R environments, version control, code review practices) in collaboration with IT and QA
Plan and manage resources and budgets for programming activities; contribute to vendor selection, governance frameworks, and performance/quality measures for delivery quality and timeliness
Represent Statistical Programming in inspections and audits; ensure documentation completeness and compliance with 21 CFR Part 11, GCP, data privacy, and company SOPs
Qualification
Required
Advanced degree (MS/PhD) in Statistics, Biostatistics, Computer Science, Mathematics, or related discipline; BS with strong relevant experience considered
10+ years of statistical programming experience in biotech/pharma/CRO settings, with 5+ years of people management
Expert hands-on proficiency in SAS (Base, Macro, STAT, GRAPH, SQL) and strong working knowledge of R; experience with Python is a plus
Demonstrated experience overseeing CROs/vendors and validating programming deliverables to CDISC standards (SDTM, ADaM)
Proven contribution to global submissions (e.g., NDA/BLA/MAA), including submission-ready datasets, TLFs, define.xml, reviewer's guides, and CSR appendices
Strong understanding of clinical development processes, ICH/GCP, FDA/EMA guidelines, and 21 CFR Part 11 compliance
Track record of building teams, establishing SOPs and standards, and implementing automation and best practices for efficiency and quality
Excellent communication, collaboration, and leadership skills; ability to translate technical concepts for non-technical stakeholders
Preferred
Therapeutic area experience in CNS/neuropsychiatry is a plus; passion for Seaport's patient-centric mission is essential
Company
Seaport Therapeutics
Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
H1B Sponsorship
Seaport Therapeutics has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2024 (1)
Funding
Current Stage
Growth StageTotal Funding
$325MKey Investors
General Atlantic
2024-10-21Series B· $225M
2024-04-09Series A· $100M
Leadership Team
Recent News
2026-01-05
2025-11-05
Company data provided by crunchbase